Award notice Supplies
2026-171 CB Suministro de medicamentos para el tratamiento de la hipercolesterolemia primaria (familiar heterocigótica y no familiar) o displidemia mixta con inhibidores de PCSK9.
Notice published in Spanish. The AI analysis summarises it for you in your language.
- Public buyer
- Consorci Hospital Clínic de Barcelona (HCB)
No consta - Place of performance
- BARCELONA
- Estimated value
- €1,306,402 excl. VAT
- Amount awarded
- €1,306,402 excl. VAT
- Planned end of contract
- 14 October 2027
likely re-tender around April 2027 - Bids received
- 2
- Form
- Framework agreement
Multi-year contract: the buyer places orders as needs arise. - Procedure
- Open procedure
Any company may submit a bid. - Publication
- 19 October 2026
- Notice language
- Spanish
AI analysis: go for it or not?
Summary in English, criteria, documents to provide and a GO / NO GO verdict in one minute.
Unlimited analyses during the 14-day Pro trial, no card needed.
Description
Contrato basado en el Acuerdo marco del consorcio de salud y de atención social de Cataluña (Exp.:CSC F 3/21). Suministro de medicamentos para el tratamiento de la hipercolesterolemia primaria (familiar heterocigótica y no familiar) o displidemia mixta con inhibidores de PCSK9.
Awarded to
3 lots
- LOTE 1 - REPATHA 140MG.
- Lote 2- PRALUENTE 75 MG
- Lote 3- PRALUENTE 150 MG
CPV codes
European codes that classify what the contract is about. They are how we find the tenders for your trade.
33600000
Winning prices for comparable contracts
- A quarter below
- €350,000
- Median
- €846,164
- A quarter above
- €2,267,877
Amounts awarded (excl. VAT) over the last 3 years for 265 contracts in the same CPV group (3360…), excluding framework agreements. Half of the contracts fall between the two quartiles. TED source: mostly contracts above the EU thresholds, so amounts tend to be high.
Similar contracts already awarded
Source : TED – Office des publications de l'Union européenne © Union européenne, données retraitées. Reference 721574-2026.